Scholars@Duke
construction release_alert
Scholars@Duke will be down for maintenance for approximately one hour starting Tuesday, 11/11 @1pm ET
cancel
Matthew Stuart McKinney

Matthew Stuart McKinney

Associate Professor of Medicine
Medicine, Hematologic Malignancies and Cellular Therapy
matthew.mckinney@duke.edu
Box 3961 Med Ctr, Durham, NC 27710
2400 Pratt Street, Suite 5000, Durham, NC 27710

Selected Publications

Expansion of an Academic Molecular Tumor Board to Enhance Access to Biomarker-Driven Trials and Therapies in the Rural Southeastern United States.

Journal Article Curr Oncol · November 16, 2024 Targeting tumor-specific molecular alterations has shown significant clinical benefit. Molecular tumor boards (MTBs) connect cancer patients with personalized treatments and clinical trials. However, rural cancer centers often have limited access to MTB ex ... Full text Link to item Cite

Comprehensive Genomic Profiling in Non-Myeloid Hematologic Malignancies Identifies Variants That Can Alter Clinical Practice.

Journal Article Hematol Rep · September 30, 2024 BACKGROUND: Comprehensive genomic profiling (CGP) is frequently adopted to direct the clinical care of myeloid neoplasms and solid tumors, but its utility in the care of lymphoid and histiocytic cancers is less well defined. METHODS: In this study, we aime ... Full text Link to item Cite

Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study.

Journal Article Lancet Haematol · September 2024 BACKGROUND: Richter transformation usually presents as an aggressive diffuse large B-cell lymphoma, occurs in up to 10% of patients with chronic lymphocytic leukaemia, has no approved therapies, and is associated with a poor prognosis. Pirtobrutinib has sh ... Full text Link to item Cite

Comparison of differing dose levels of methotrexate for patients with primary central nervous system lymphoma.

Journal Article J Oncol Pharm Pract · April 2024 INTRODUCTION: It has long been established that high-dose methotrexate is an essential part of therapy for primary central nervous system lymphoma. When regimens utilizing high-dose methotrexate were first studied, a dose of 8 g/m2 was used. More recently, ... Full text Link to item Cite

Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium.

Journal Article J Hematol Oncol · December 16, 2023 BACKGROUND: Patients with mantle cell lymphoma (MCL) exhibit a wide variation in clinical presentation and outcome. However, the commonly used prognostic models are outdated and inadequate to address the needs of the current multidisciplinary management of ... Full text Link to item Cite

Prevalence and significance of clonal hematopoiesis of indeterminate potential in lung transplant recipients.

Journal Article BMC Pulm Med · October 30, 2023 BACKGROUND: Clonal hematopoiesis of indeterminate potential (CHIP), the age-related acquisition of somatic mutations that leads to an expanded blood cell clone, has been associated with development of a pro-inflammatory state. An enhanced or dysregulated i ... Full text Link to item Cite

Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study.

Journal Article EClinicalMedicine · September 2023 BACKGROUND: Parsaclisib, a potent and highly selective PI3Kδ inhibitor, has shown clinical benefit in patients with relapsed or refractory (R/R) B-cell malignancies. This phase 2 study (CITADEL-203; NCT03126019, EudraCT 2017-001624-22) assessed efficacy an ... Full text Link to item Cite

Combinatorial Efficacy and Toxicity of an Engineered Toxin Body MT-3724 with Gemcitabine and Oxaliplatin in Relapsed or Refractory Diffuse Large B Cell Lymphoma.

Journal Article Cancer Invest · January 31, 2023 MT-3724 is an engineered direct-kill immunotoxin comprised of a CD20-specific scFv fused to a Shiga-like toxin subunit. In this phase IIa study, eight patients with relapsed diffuse large B-cell lymphoma were treated with MT-3724 combined with gemcitabine ... Full text Link to item Cite

First in Time: The Place of Tribes in Governing the Colorado River System

Journal Article NATURAL RESOURCES JOURNAL · 2023 Cite

Dietary therapy in abdominal aortic aneurysm — Insights from clinical and experimental studies

Journal Article Frontiers in Cardiovascular Medicine · September 21, 2022 Abdominal aortic aneurysm (AAA) is a prevalent vascular disease with high mortality rates upon rupture. Despite its prevalence in elderly populations, there remain limited treatment options; invasive surgical repair, while risky, is the only therap ... Full text Cite

Characterization of low-grade arthralgia, myalgia, and musculoskeletal pain with ibrutinib therapy: pooled analysis of clinical trials in patients with chronic lymphocytic leukemia and mantle cell lymphoma.

Journal Article Leuk Lymphoma · July 2022 Joint and muscle pain, including arthralgia, myalgia, and musculoskeletal pain, are among the common adverse events (AEs) reported for ibrutinib, a once-daily Bruton's tyrosine kinase inhibitor approved for the treatment of various B-cell malignancies, inc ... Full text Link to item Cite

Genomic and Precision Medicine: Oncology, Third Edition

Book · January 1, 2022 Genomic and Precision Medicine: Oncology, Third Edition focuses on the applications of genome discovery as research points to personalized cancer therapies. Each chapter is organized to cover the application of genomics and personalized medicine tools and ... Full text Cite

Introduction and overview of cancer precision medicine

Chapter · January 1, 2022 While cancer causes premature death in millions of persons around the globe yearly, in the last few years incredible advances have been made in our understanding of molecular drivers of cancers. Cancer treatment programs have benefited significantly from t ... Full text Cite

Preface

Book · January 1, 2022 Full text Cite

Origin of Non-Hodgkin Lymphoma and Therapeutic Targets

Chapter · January 1, 2022 Non-Hodgkin lymphoma is the most common type of blood cancer. Over the past 2 decades, discoveries in basic immunology and the pathogenesis of malignancies have significantly advanced our understanding of the origin of lymphoid neoplasms. These diseases ha ... Full text Cite

Genomic and Transcriptional Characterization of Primary Mediastinal Large B Cell Lymphoma

Conference Blood · November 5, 2021 AbstractIntroduction: Primary mediastinal large B-cell lymphoma (PMBL) is a rare non-Hodgkin lymphoma subtype that occurs predominantly in young adults, with an overall favorable prognosis. The cell of origi ... Full text Cite

Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma: Primary Analysis from a Phase 2 Study (CITADEL-203)

Conference Blood · November 5, 2021 AbstractBackground: Follicular lymphoma (FL) is the second most common form of non-Hodgkin lymphoma (NHL) in Western countries, accounting for 20-30% of all NHLs (Hübel K. Hemasphere. 2020;4:e317). While mos ... Full text Cite

The Atlas of Blood Cancer Genomes (ABCG) Project: A Comprehensive Molecular Characterization of Leukemias and Lymphomas

Conference Blood · November 5, 2021 AbstractIntroductionBlood cancers are collectively common and strikingly heterogeneous diseases both clinically and molecularly. According to the WHO taxonomy, there are over ... Full text Cite

Primary Mediastinal (Thymic) Large B-Cell Lymphoma: Fidelity of Diagnosis Using WHO Criteria.

Journal Article Clin Lymphoma Myeloma Leuk · May 2021 PURPOSE: Diagnosing primary mediastinal (thymic) large B-cell lymphoma (PMBCL) is challenging because it is a clinicopathologic entity that shares characteristics with other lymphomas and lacks pathognomonic features. We sought to investigate the fidelity ... Full text Link to item Cite

Epigean Crayfish of the Potomac River Basin in West Virginia: Zoogeography, Natural History and Conservation

Journal Article Freshwater Crayfish · April 15, 2021 AbstractCrayfish are an aquatic fauna of conservation concern, yet regional studies are lacking on zoogeography and life history. We compared recent and historical species distribution data and assessed conservation stan ... Full text Cite

Results and Clinical Utilization of Foundation Medicine Molecular Tumor Profiling in Uterine and Ovarian Cancers.

Journal Article Target Oncol · January 2021 BACKGROUND: Recent advances in next-generation sequencing have allowed for an increase in molecular tumor profiling. OBJECTIVE: We sought to assess the actionability and clinical utilization of molecular tumor profiling results obtained via Foundation Medi ... Full text Link to item Cite

Implementation of a Molecular Tumor Registry to Support the Adoption of Precision Oncology Within an Academic Medical Center: The Duke University Experience.

Journal Article JCO Precis Oncol · 2021 UNLABELLED: Comprehensive genomic profiling to inform targeted therapy selection is a central part of oncology care. However, the volume and complexity of alterations uncovered through genomic profiling make it difficult for oncologists to choose the most ... Full text Link to item Cite

Single-Agent Mosunetuzumab Is a Promising Safe and Efficacious Chemotherapy-Free Regimen for Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Conference Blood · November 5, 2020 Introduction: Up to 30% of patients (pts) aged ≥75 years do not receive standard chemoimmunotherapy (CIT) as first-line (1L) treatment for diffuse large B-cell lymphoma (DLBCL) due to concerns about frailty and comorbidities. Poor outcomes are comm ... Full text Cite

Successful Treatment of Mature T-Cell Lymphoma with Allogeneic Stem Cell Transplantation: The Largest Multicenter Retrospective Analysis

Conference Blood · November 5, 2020 Background: Allogeneic hematopoietic transplantation (HCT) is frequently considered for patients (pts) with relapsed T-cell lymphoma (TCL) and less often as consolidation of initial therapy. Outcomes from prior registry data show that only 31% of p ... Full text Cite

Phase 2 Study Evaluating the Efficacy and Safety of Parsaclisib in Patients with Relapsed or Refractory Follicular Lymphoma (CITADEL-203)

Conference Blood · November 5, 2020 Background: Follicular lymphoma (FL) is the most common subtype of indolent non-Hodgkin lymphoma (NHL). Although most patients with FL respond well to first-line therapy, they will inevitably relapse, and the subsequent course is often characterize ... Full text Cite

Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.

Journal Article J Natl Compr Canc Netw · June 2020 The NCCN Clinical Practice Guidelines in Oncology for Hodgkin Lymphoma (HL) provide recommendations for the management of adult patients with HL. The NCCN panel meets at least annually to review comments from reviewers within their institutions, examine re ... Full text Link to item Cite

Whole Exome and Transcriptome Sequencing in 1042 Cases Reveals Distinct Clinically Relevant Genetic Subgroups of Follicular Lymphoma.

Journal Article Blood · November 13, 2019 DISCLOSURES: Koff: Burroughs Wellcome Fund: Research Funding; V Foundation: Research Funding; Lymphoma Research Foundation: Research Funding; American Association for Cancer Research: Research Funding. Leppä:Roche: Honoraria, Research Funding; Takeda: Hono ... Full text Link to item Cite

A Phase 1 Study of ACTR087 in Combination with Rituximab, in Subjects with Relapsed or Refractory CD20-Positive B-Cell Lymphoma

Conference Blood · November 13, 2019 Background: The Antibody-Coupled T-cell Receptor (ACTR) platform is an autologous engineered T-cell therapy that combines the cell-killing ability of T cells and the tumor-targeting ability of co-administered antibodies to exert potent antitumor im ... Full text Cite

Real World Use of IDH2- Targeted Inhibitors in a Single Academic Medical Center Experience Since Enasidenib FDA-Approval

Conference Blood · November 13, 2019 BackgroundEnasidenib, a novel inhibitor of isocitrate dehydrogenase 2 (IDH2), offers targeted therapy to the ~12% of acute myeloid leukemia (AML) patients in which a recurrent IDH2 mutation exists. While currently o ... Full text Cite

A Phase 2a Open-Label Study to Investigate Safety and Tolerability (including the MTD), Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of MT-3724 in Combination with Gemcitabine and Oxaliplatin in Subjects with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Conference Blood · November 13, 2019 Introduction:Approximately 40% of all newly diagnosed Diffuse large B-cell lymphoma (DLBCL) patients are either refractory or relapsed following initial therapy, and represent a population with high unmet need for n ... Full text Cite

Hepatosplenic T-cell lymphoma

Chapter · October 23, 2019 Full text Cite

New horizons in the treatment and management of Lymphoma: Novel therapies for improved patient outcomes

Journal Article Journal of Managed Care Medicine · January 1, 2019 The treatment of lymphoma continues to evolve with a better understanding of the genetics, cell markers, and tumor microenvironment which all play a role in the growth and proliferation of the disease. Several targeted and immunotherapies are now available ... Cite

Novel Mechanisms for Resistance to Targeted Therapy Identified through Machine Learning Approaches in 1167 RNA-Seq Drug Exposure Profiles in Lymphoma

Conference Blood · November 29, 2018 AbstractIntroduction:Diffuse large B cell lymphoma (DLBCL) is a clinically heterogeneous disease. While roughly half of the patients respond well to standard R-CHOP therapy, ... Full text Cite

Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer.

Journal Article Cancer Discov · February 2018 "Liquid biopsy" approaches analyzing cell-free DNA (cfDNA) from the blood of patients with cancer are increasingly utilized in clinical practice. However, it is not yet known whether cfDNA sequencing from large cohorts of patients with cancer can detect ge ... Full text Link to item Cite

ACTR087, Autologous T Lymphocytes Expressing Antibody Coupled T-Cell Receptors (ACTR), Induces Complete Responses in Patients with Relapsed or Refractory CD20-Positive B-Cell Lymphoma, in Combination with Rituximab

Conference Blood · December 7, 2017 AbstractBackground: Autologous T cells engineered to express the universal ACTR chimeric receptor kill tumors through interactions with tumor-targeting antibodies [Kudo, Cancer Res. 2014]. Preclinical findin ... Full text Cite

Factors shaping avian alien species richness in Australia vs Europe

Journal Article Diversity and Distributions · November 2017 AbstractAimWe aim to examine the relative importance of human activity‐related and natural variables in shaping spatial patterns of alien bird species richness at the continental scale for ... Full text Cite

Thermal biology of Osmia cornifrons (Hymenoptera: Megachilidae) eggs and larvae

Journal Article Journal of Apicultural Research · August 8, 2017 Full text Cite

Enteropathy-associated T cell lymphoma subtypes are characterized by loss of function of SETD2.

Journal Article J Exp Med · May 1, 2017 Enteropathy-associated T cell lymphoma (EATL) is a lethal, and the most common, neoplastic complication of celiac disease. Here, we defined the genetic landscape of EATL through whole-exome sequencing of 69 EATL tumors. SETD2 was the most frequently silenc ... Full text Link to item Cite

The Genetic Basis of Hepatosplenic T-cell Lymphoma.

Journal Article Cancer Discov · April 2017 Hepatosplenic T-cell lymphoma (HSTL) is a rare and lethal lymphoma; the genetic drivers of this disease are unknown. Through whole-exome sequencing of 68 HSTLs, we define recurrently mutated driver genes and copy-number alterations in the disease. Chromati ... Full text Link to item Cite

Origin of Non-Hodgkin Lymphoma

Chapter · January 1, 2017 Full text Cite

SETD2 Functional Loss through Mutation or Genetic Deletion Promotes Expansion of Normal and Malignant γδ T Cells through Loss of Tumor Suppressor Function and Upregulation of Oncogenic Pathways

Conference Blood · December 2, 2016 AbstractPeripheral T cell lymphomas (PTCL) of γδ T cell origin including subsets of hepatosplenic T cell lymphoma (HSTL) and enteropathy associated T cell lymphoma (EATL) are characterized by short survival ... Full text Cite

GNA13 loss in germinal center B cells leads to impaired apoptosis and promotes lymphoma in vivo.

Journal Article Blood · June 2, 2016 GNA13 is the most frequently mutated gene in germinal center (GC)-derived B-cell lymphomas, including nearly a quarter of Burkitt lymphoma and GC-derived diffuse large B-cell lymphoma. These mutations occur in a pattern consistent with loss of function. We ... Full text Link to item Cite

Connecting people and places: the emerging role of network governance in large landscape conservation

Journal Article Frontiers in Ecology and the Environment · April 2016 The most important land and water issues facing North America and the world – including land‐use patterns, water management, biodiversity protection, and climate adaptation – require innovative governance arrangements. Most of these issues need to ... Full text Cite

Clinical and Immunomodulatiory Outcomes of Microtransplantation for AML

Conference Biology of Blood and Marrow Transplantation · March 2016 Full text Cite

Resolving water conflicts in the American West

Journal Article Water Policy · August 1, 2015 The American West is defined first and foremost by aridity, scarcity, and variability of water resources. In response to this geographic imperative, the region has evolved a robust menu of legal, institutional, and community-based approaches to man ... Full text Cite

Merkel cell carcinoma with partial B-cell blastic immunophenotype: a potential mimic of cutaneous richter transformation in a patient with chronic lymphocytic lymphoma.

Journal Article Am J Dermatopathol · February 2014 Merkel cell polyomavirus (MCPyV) is a DNA virus whose pathogenic mechanisms in Merkel cell carcinoma (MCC) are still being unraveled. Emerging reports of an association between MCPyV and chronic lymphocytic lymphoma (CLL) have begun to broaden our understa ... Full text Link to item Cite

PAK1 mediates resistance to PI3K inhibition in lymphomas.

Journal Article Clin Cancer Res · March 1, 2013 PURPOSE: The phosphoinositide 3-kinase (PI3K) pathway is known to play an active role in many malignancies. The role of PI3K inhibition in the treatment of lymphomas has not been fully delineated. We sought to identify a role for therapeutic PI3K inhibitio ... Full text Link to item Cite

Origin of Non-Hodgkin Lymphoma

Chapter · 2013 This leading text reflects both the new direction and explosive growth of the field of hematology. ... Cite

The genetic landscape of mutations in Burkitt lymphoma.

Journal Article Nat Genet · December 2012 Burkitt lymphoma is characterized by deregulation of MYC, but the contribution of other genetic mutations to the disease is largely unknown. Here, we describe the first completely sequenced genome from a Burkitt lymphoma tumor and germline DNA from the sam ... Full text Link to item Cite

ID3 Is a Novel Tumor Suppressor Gene in Burkitt Lymphom

Conference Blood · November 16, 2012 AbstractAbstract 898Burkitt Lymphoma (BL) is a highly proliferative form of non-Hodgkin lymphoma and is characterized by translocation of the C-MYC gene to the immunoglobulin ... Full text Cite

Alterations in Metabolism and Mitochondrial Respiration Are Associated with Response to Targeted Inhibition of WNT Signaling in Lymphomas

Conference Blood · November 16, 2012 AbstractAbstract 778BackgroundWnt signaling is a highly conserved pathway with diverse roles in proli ... Full text Cite

Depleting regulatory T cells with arginine-rich, cell-penetrating, peptide-conjugated morpholino oligomer targeting FOXP3 inhibits regulatory T-cell function.

Journal Article Cancer Gene Ther · January 2012 CD4+CD25+regulatory T cells (T(reg)) impair anti-tumor and anti-viral immunity. As there are higher T(reg) levels in cancer patients compared with healthy individuals, there is considerable interest in eliminating them or altering their function as part of ... Full text Link to item Cite

Erythropoietin for oncology supportive care.

Journal Article Exp Cell Res · May 15, 2011 Recombinant human erythropoietin (rhEPO), the prototype erythropoiesis-stimulating agent developed in the 1980s, was among the first recombinant human proteins to be marketed for clinical use in the oncology setting. Anemia is a frequent concern in patient ... Full text Link to item Cite

Erythropoiesis-stimulating agents in older adults with cancer

Chapter · January 1, 2010 Introduction The prevalence of anemia in older persons is higher than in the general population and is associated with significant clinical symptoms and poorer prognosis in this group. An increased incidence of cancer and the use of cytotoxic agents in thi ... Full text Cite

Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine.

Journal Article Clin Cancer Res · April 15, 2009 PURPOSE: Wilms' tumor protein (WT1) is overexpressed in most leukemias and many solid tumors and is a promising target for tumor immunotherapy. WT1 peptide-based cancer vaccines have been reported but have limited application due to HLA restriction of the ... Full text Link to item Cite

Advances in immunotherapy for colorectal malignancies

Journal Article Current Colorectal Cancer Reports · October 1, 2008 In the past decade, numerous advances have been made in resection, adjuvant treatment, and targeted therapies for colorectal malignancies; however, survival in the setting of metastatic disease treated with the most recent guideline-based therapy is only a ... Full text Cite

Evaluating Community-Based Collaboration on Federal Lands and Resources

Journal Article Society & Natural Resources · April 9, 2008 Full text Cite

The promise and the challenge of cooperative conservation

Journal Article FRONTIERS IN ECOLOGY AND THE ENVIRONMENT · 2007 Cite

The challenge of funding consensus-building processes

Journal Article Negotiation Journal · 1997 Full text Cite

CARDIOVASCULAR EFFECTS OF ISOFLURANE AND HALOTHANE IN YOUNG AND ELDERLY ADULT PATIENTS

Journal Article British Journal of Anaesthesia · November 1993 Full text Cite

DICLOFENAC FOR DAY-CARE ARTHROSCOPY SURGERY: COMPARISON WITH A STANDARD OPIOID THERAPY

Journal Article British Journal of Anaesthesia · November 1990 Full text Cite

EFFECT OF FLUMAZENIL ON MIDAZOLAM-INDUCED AMNESIA

Journal Article British Journal of Anaesthesia · August 1990 Full text Cite

DICLOFENAC SODIUM FOR DAY CASE ARTHROSCOPY

Conference BRITISH JOURNAL OF CLINICAL PHARMACOLOGY · 1990 Cite

Characteristics of the Pharmaseal continuous flushing device

Journal Article Anaesthesia · March 1989 SummaryPharmaseal continuous flushing devices were tested with regard to flow characteristics into simulated arterial and venous pressure systems. Two driving pressures were used and it was found that var ... Full text Cite

Concealed intra‐arterial injection of thiopentone

Journal Article Anaesthesia · July 1988 Full text Cite

A new technique for sleeve resection and major bronchial resection using twin catheters and high frequency jet ventilation

Journal Article Anaesthesia · January 1988 SummaryA new anaesthetic technique that uses two catheters combined with high frequency jet ventilation for sleeve resection of the major bronchus and carina is described. The advantages and disadvantages ... Full text Cite

Water resources planning: A collaborative, consensus‐building approach

Journal Article Society & Natural Resources · January 1988 Full text Cite

Hanging drop and extradural pressures

Journal Article Anaesthesia · October 1987 Full text Cite